AURX
Nuo Therapeutics, Inc.2.0000
-0.1500-6.98%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
96.16MP/E (TTM)
-Basic EPS (TTM)
-0.05Dividend Yield
0%Recent Filings
8-K
Secures $1M loan from insiders
Nuo Therapeutics secured $1.0M initial funding on January 23, 2026, from lenders including director Scott Pittman and 5% owner Paul Jacobs, with $600K more possible September 30. Notes at 10% interest (12% post-second tranche) mature December 31, 2028, secured by all assets for working capital. Warrants issued cover fees, capital, interest. Lenders hold first liens.
8-K
Annual meeting results strong
Nuo Therapeutics held its 2025 Annual Meeting on December 16, electing David E. Jorden, Paul D. Mintz, Scott M. Pittman, and C. Eric Winzer to its board with overwhelming support—over 33 million for votes each, minimal withheld. Shareholders ratified MaloneBailey LLP as auditors for fiscal 2025 via near-unanimous 35.9 million for votes. Say-on-pay passed handily too. Continuity locked in.
10-Q
Q3 FY2025 results
Nuo Therapeutics tripled Q3 revenue to $1.0M (y/y), blending $957K product sales and $75K distribution fees, yet narrowed operating loss to $540K from $577K while gross margin slipped to 61% from 73% on low-margin centrifuge sales to Smith+Nephew. YTD revenue doubled to $2.2M, operating loss widened slightly to $1.9M amid sales commissions and professional fees, with net loss steady at $(0.04) per share on 47M diluted shares. Cash hit $515K after $905K equity raises offset $442K operating burn; $1.5M upfront from March 2025 Smith+Nephew deal (5-year term, ~$500K annual minimums) fuels deferred revenue of $1.35M. No debt. Single suppliers pose supply risks.
8-K
Exec salary hikes approved
Nuo Therapeutics boosted salaries for CEO David Jorden to $325,000 and CSOO Peter Clausen to $290,000, effective October 1, 2025, citing 2025's improved business and financial condition. The board set the 2025 Annual Meeting for December 16, 2025, in Houston, with proxy proposals due by October 20. Raises reward progress.
10-Q
Q2 FY2025 results
Nuo Therapeutics nearly doubled Q2 revenue to $700K (y/y +92%, from $365K), fueled by product sales jumping to $625K while adding $75K initial license revenue from the March 31, 2025 Smith+Nephew private-label deal (upfront $1.5M deferred over 5 years). Gross profit hit $541K (77% margin) yet operating loss widened to $652K on $1.2M SG&A, driven by legal/accounting fees, commissions, and consulting. Operating cash flow swung positive at $264K YTD (from -$1.3M y/y) on deferred revenue, ending with $316K cash but $825K stockholders' deficit; no debt. Subsequent July 30 equity raise added $791K. Customer concentration lingers.
AUPH
Aurinia Pharmaceuticals Inc
15.85+0.16
AURA
Aura Biosciences, Inc.
6.18-0.15
AVTX
Avalo Therapeutics, Inc.
18.82+1.12
BRTX
BioRestorative Therapies, Inc.
1.08-0.03
CELU
Celularity Inc.
1.35-0.05
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
MDWD
MediWound Ltd.
18.77-0.28
NBY
NovaBay Pharmaceuticals, Inc.
3.16+0.45
NRIX
Nurix Therapeutics, Inc.
18.84-0.17
RMTG
Regenerative Medical Technology
0.04+0.00